Background

Polyphenols have been implicated to have numerous health benefits, and much of these are attributed to the metabolism of phenolic compounds by gut microbiota. The aim of this systematic review was to examine the effects of polyphenol consumption in modulating gut microbiota and anthropometric variables/clinical markers in randomised controlled trials (RCTs).

Scope and approach

We systematically searched PubMed, Scopus, Embase, Cochrane library and Web of Science databases from inception to31^st July 2019 following the PRIMSA guidelines.RCTs reporting on the effects of polyphenol consumption on gut microbes, and anthropometric variables (body weight, BMI, waist circumference, hip circumference)/clinical markers (CVD markers, and colon cancer markers) were included in this review. The methodological quality of the studies was assessed using the Cochrane Collaboration's risk of bias tool and Jadad scale.

Key findings and conclusion

Seventeen RCTs met the inclusion criteria. Ten studies highlighted significant changes in the microbial profile, while 15 reported significant changes in CVD and colon cancer markers. The univariate correlation data showed a significant correlation between certain genera with clinical markers, specifically TNFα, cholesterol, HDL, CRP, and LPS. In the multivariate analysis, negative correlations were reported between Lactobacillus and TAG, CRP, Bacteroides with TAG, HDL, DBP, and SBP, and Bifidobacterium with cholesterol and CRP. This review supports the notion of polyphenols as prebiotics as significant modulation of intestinal microbes affecting mainly CVD markers were found in most of the RCTs. Further well-structured trials with larger sample size, longer duration, and high-throughput molecular techniques, will provide more conclusive results.

Protocol registration number

PROSPERO; CRD42017077577;

中文翻译：

---

多酚的益生元潜力，其对肠道菌群和人体测量/临床指标的影响：随机对照试验的系统综述

背景

涉及多酚具有许多健康益处，其中许多归因于肠道菌群对酚类化合物的代谢。该系统评价的目的是检验随机对照试验（RCT）中多酚消耗对调节肠道菌群和人体测量学变量/临床标志物的影响。

范围和方法

我们根据PRIMSA指南从成立到2019年7月31^日，系统搜索了PubMed，Scopus，Embase，Cochrane图书馆和Web of Science数据库.RCT报告了多酚摄入量对肠道微生物的影响以及人体测量学变量（体重，BMI，腰围） ，髋围）/临床标记物（CVD标记物和结肠癌标记物）包括在本评价中。研究的方法学质量使用Cochrane Collaboration的偏倚风险工具和Jadad量表进行评估。

主要发现和结论

17个RCT符合纳入标准。十项研究强调了微生物谱的显着变化，而十五项报告了CVD和结肠癌标志物的显着变化。单变量相关性数据显示某些属与临床标志物，特别是TNFα，胆固醇，HDL，CRP和LPS之间存在显着相关性。在多变量分析中，乳酸菌与TAG，CRP，拟杆菌与TAG，HDL，DBP和SBP以及双歧杆菌之间呈负相关。与胆固醇和CRP。该评论支持多酚作为益生元的概念，因为在大多数RCT中发现了主要影响CVD标志物的肠道微生物的显着调节。具有更大样本量，更长持续时间和高通量分子技术的进一步结构合理的试验将提供更具结论性的结果。

协议注册号

PROSPERO; CRD42017077577；